Ardelyx (ARDX) Morgan Stanley 24th Annual Global Healthcare Conference summary

Business progress and financial outlook

• Two commercial products, IBSRELA and XPHOZAH, are driving strong revenue growth, with 2024 revenue expected to approach $500 million and profitability targeted for 2027.

• Intellectual property extends to 2042, supporting long-term value creation and ongoing investment in lifecycle management.

• Guidance was revised due to payer pressures and prior authorization hurdles, but demand for both products remains robust.

• OpEx is stable under $500 million, with sales growth expected to outpace expenses, supporting sustained profitability.

• Cash at the end of Q2 was nearly $282 million, with $250 million in debt, and ongoing strong cash generation is anticipated.

Commercial strategy and market positioning

• IBSRELA targets a large IBS-C market, aiming for a sub-10% share to reach $1 billion in sales, with growth rate adjustments extending the timeline.

• Specialty pharmacy network (IPN) is being prioritized over retail to reduce prescription abandonment and improve refill rates.

• Product differentiation is based on a unique mechanism of action and superior pain benefit for IBS-C patients, positioning as a second- or third-line therapy.

• Over 70% of patients on secretagogues are unsatisfied, creating a significant opportunity for IBSRELA.

• The ongoing CIC trial (ACCEL study) aims to expand indications and simplify prescribing for physicians, with a readout expected mid-next year.

XPHOZAH market approach and reimbursement

• XPHOZAH addresses hyperphosphatemia in dialysis patients, focusing on Medicaid and commercial sectors due to a strategic decision to avoid the Medicare bundled payment system.

• The end of the TDAPA period in 2027 is expected to shift market dynamics and engagement with dialysis organizations.

• A new quality measure for phosphorus management may provide a tailwind for adoption.

• Revenue guidance for XPHOZAH is $110–$120 million, with future updates pending market evolution.

• The product offers a novel mechanism and clinical benefits not previously available with binders.